Matthew J. Pietras
Keine laufenden Positionen mehr
Profil
Matthew J.
Pietras worked as the Chief Operating & Financial Officer at StageZero Life Sciences Ltd.
in 2021-2022.
Prior to that, he was the Treasurer & Controller at Viela Bio, Inc. from 2017-2019.
He also worked as the Vice President-Finance at CiVi Biopharma, Inc. His education includes an MBA from The Johns Hopkins University and an undergraduate degree from The Pennsylvania State University.
Ehemalige bekannte Positionen von Matthew J. Pietras
Unternehmen | Position | Ende |
---|---|---|
STAGEZERO LIFE SCIENCES LTD. | Finanzdirektor/CFO | 26.05.2022 |
VIELA BIO, INC. | Comptroller/Controller/Auditor | 01.01.2019 |
CiVi Biopharma, Inc.
CiVi Biopharma, Inc. Pharmaceuticals: MajorHealth Technology CiVi Biopharma, Inc. engages in the research and development of activities focusing on creating novel therapies against cardiovascular and metabolic diseases. The company was founded by Henrik Rum in 2016 and is headquartered in Wilmington, DE. | Finanzdirektor/CFO | - |
Ausbildung von Matthew J. Pietras
The Pennsylvania State University | Undergraduate Degree |
The Johns Hopkins University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
STAGEZERO LIFE SCIENCES LTD. | Health Technology |
Private Unternehmen | 2 |
---|---|
CiVi Biopharma, Inc.
CiVi Biopharma, Inc. Pharmaceuticals: MajorHealth Technology CiVi Biopharma, Inc. engages in the research and development of activities focusing on creating novel therapies against cardiovascular and metabolic diseases. The company was founded by Henrik Rum in 2016 and is headquartered in Wilmington, DE. | Health Technology |
Viela Bio, Inc.
Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |